Piramal Pharma Limited is a global pharmaceutical company with a diversified portfolio, focusing on three key segments: Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO) providing end-to-end drug development and manufacturing services; Piramal Critical Care, a major player in complex hospital generics, particularly inhaled anesthetics; and the India Consumer Healthcare business, which is among the fastest-growing in the over-the-counter market with strong brands like Lacto Calamine and i-pill. Operating 17 facilities worldwide and distributing in over 100 countries, the company leverages an integrated network to serve a diverse client base, including big pharma, biotech, and generic firms. With a strategic focus on innovation, quality, and operational excellence, Piramal Pharma has achieved significant growth, reporting ₹6,559 crore in revenue in FY22, with 78% from international markets, particularly the U.S. The company’s recent demerger from Piramal Enterprises in 2022 and a 20% investment from The Carlyle Group in 2020 have strengthened its financial position, enabling capacity expansion and acquisitions to drive future growth. Despite challenges like supply chain disruptions and pricing pressures, Piramal Pharma is well-positioned for sustained growth, aiming to double its revenue to $2 billion by FY30, driven by its CDMO expertise, differentiated offerings, and expanding consumer healthcare presence